The Fellow on Call: The Heme/Onc Podcast
Rouleaux University Medical Center
Episode 168: Pancreatic Cancer Series, Pt. 3 – Borderline Resectable…
Bu podcast hakkında
We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.
Bölümler
176 bölümden en yeni 20 bölüm
- Episode 168: Pancreatic Cancer Series, Pt. 3 – Borderline Resectable and Locally Advanced Disease · Bölüm 168This week we continue our Pancreatic Cancer series with the two middle categories of non-metastatic disease: borderline resectable and locally advanced. Using the case of a…
- Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease · Bölüm 167This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of…
- Episode 166: Pancreatic Cancer Series, Pt. 1 – Biology, Diagnosis, and Staging · Bölüm 166This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and…
- Episode 165: CLL Updates Series, Pt. 2 – Relapsed/Refractory in 2026 · Bölüm 165This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy…
- Episode 164: CLL Updates Series, Pt. 1 – Frontline Therapy in 2026 · Bölüm 164This week we kick off a two-part update to our CLL series, covering what has changed in frontline management since our original episodes. Using the case of a 68-year-old man with…
- Episode 163: Head and Neck Cancer Series, Pt. 5 – Recurrent, Relapsed, and Metastatic Disease · Bölüm 163This week the Head and Neck series turns to what happens when local therapy isn't enough — recurrent, relapsed, and metastatic disease. Using the case of a woman with a laryngeal…
- Episode 162: Head and Neck Cancer Series, Pt. 4 – Discussion with Radiation Oncology · Bölüm 162This week the Head and Neck series turns to radiation oncology, with guest Dr. David Palma, a Professor and Radiation Oncologist at the Verspeeten Family Cancer Centre and…
- Episode 161: Career Development Series- Building a Career in Clinical Research · Bölüm 161This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH…
- Episode 160: Head and Neck Cancer Series, Pt. 3 – Discussion with ENT · Bölüm 160Throughout this series, we have discussed how multidisciplinary the management of head and neck cancer is and the critical role that our surgical colleagues play in the…
- Episode 159: Head and Neck Cancer Series, Pt. 2 – Locoregional Disease · Bölüm 159This week we get into treatment. Building on Part 1's (episode 158: https://www.thefellowoncall.com/tfocpodcast/hncintro) workup and staging, we walk through three cases to…
- Episode 158: Head and Neck Cancer Series, Pt. 1 - Introduction · Bölüm 158This week, we kick off our Head and Neck Cancer series. Using the case of a man with a painless neck mass, we build a framework for the whole series. Content: - Why head and…
- Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP · Bölüm 157This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we…
- Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory · Bölüm 156This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we…
- Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management · Bölüm 155This week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do…
- Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series) · Bölüm 154This week, we are so excited to share the second episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH…
- Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing · Bölüm 153Therapy, Maintenance, and Relapsed/Refractory Sequencing This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every…
- Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly · Bölüm 152This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the…
- Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026) · Bölüm 151In this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly…
- Episode 150: Myeloma Series, Pt. 10 - Role of CAR T for relapsed/refractory multiple myeloma (2026) · Bölüm 150In this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next…
- Episode 149: Myeloma Series, Pt. 9 - Maintenance for Multiple Myeloma (2026) · Bölüm 149This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who…








